Suppliers / Zhejiang Liaoyuan Pharmaceuticals

Zhejiang Liaoyuan Pharmaceuticals

China Updated 9 July 2026

Zhejiang Liaoyuan Pharmaceuticals is an API manufacturer based in China. It holds 6 active US drug master files across a filed portfolio of 6 molecules.

6
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Questions about Zhejiang Liaoyuan Pharmaceuticals

Does Zhejiang Liaoyuan Pharmaceuticals hold a US DMF or a CEP?
Zhejiang Liaoyuan Pharmaceuticals holds 6 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Zhejiang Liaoyuan Pharmaceuticals make?
6 molecules are on record against Zhejiang Liaoyuan Pharmaceuticals, including Apixaban, Clopidogrel, Duloxetine and Ferric Carboxymaltose. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Checking Zhejiang Liaoyuan Pharmaceuticals?

Ask Fred what the record holds on Zhejiang Liaoyuan Pharmaceuticals, including filings and inspection history.

Chat with Fred, your AI analyst
Opens WhatsApp. Free to start.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability